Recent Updates
Recently added Catalysts

RPX2003

Phase 1

Healthy Volunteers | Small molecule | Other |Novartis AG|Last Updated: Dec 3, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

Clinical trial landscape

RPX2003 · 1 trial · 2 indications

Phase 1 1
NCT01702649Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult SubjectsHealthy Volunteers
COMPLETED36 Analytics
PHASE1COMPLETED
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
Healthy VolunteersUnlock trial analytics

Study Endpoints

Primary Endpoints

Safety from baseline through the end of the study.
Study Day 1 to 13.

Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.

Secondary Endpoints

Composite of PK parameters RPX2003 & placebo following single dose administration.
Part 1A Study Day 1 to 3.
Composite of PK parameters RPX2003 & placebo following multiple dose administration.
Part 1B Day 4 to 12
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
RPX2003 (Biapenem)EXPERIMENTALSingle and multiple dose of RPX2003 (Biapenem).
Normal SalinePLACEBO_COMPARATORSingle and multiple doses of normal saline.

Interventions

NameTypeDescription
RPX2003 (Biapenem)DRUGSix (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation. Single dose followed by multiple dose, three times a day.
PlaceboDRUGSix (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation. Single dose followed by multiple dose, three times a day.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy adult males and/or females, 18 to 55 years of age * Body mass index (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive). * Medically healthy with clinically insignificant screening results * Non-tobacco/nicotine-containing product users for...

Countries:United States
Unlock Eligibility Criteria